Meta Pixel

News and Announcements

Atomo Diagnostics – CEO Interview

  • Published October 27, 2015 6:09PM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.

Atomo launched its first test on the platform, AtomoRapid HIV, in 2014. Since launch, AtomoRapid tests have quickly established themselves as a “best in class” solution for professional use diagnostic screening.

With tests now commercialised for HIV and malaria and a rapid Ebola test ready for launch later this year, Atomo is disrupting global RDT markets where convenience, usability and safety have for many years been largely overlooked.

Please listen to John Kelly, CEO of Atomo Diagnostics below.

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Capital Insights
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain

In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]

Join over 45,000+ sophisticated investors

Join Now